Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study

Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study

BackgroundInterleukin-13 receptor α 2 (IL13Rα2) is a promising tumor-directed antigen of malignant glioma (MG). Here, we examine the efficacy and safety of T cells containing a YYB-103 chimeric antigen receptor (CAR) that can preferentially bind to IL13Rα2 on MG cells.MethodsIL13 was modified on the...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Kiwan Kim, Ho-Shin Gwak, Nayoung Han, Eun Kyung Hong, Beom K. Choi, Sangeun Lee, Soyoung Choi, Ju-Hwang Park, Ji-Hye Seok, Yeongha Jeon, Hyuntae Cho, Song-Jae Lee, Yura Lee, Ki Taek Nam, Seong-Won Song
Format: article
Langue:EN
Publié: Frontiers Media S.A. 2021
Sujets:
chimeric antigen receptor T cell
immunohistochemistry
interleukin-13
malignant glioma
immunotherapy
Immunologic diseases. Allergy
RC581-607
Accès en ligne:https://doaj.org/article/dc3012fd96854bd3994a62b55e0a09fb
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/dc3012fd96854bd3994a62b55e0a09fb

Documents similaires